Metabolic and skeletal effects of low and high doses of @entity18279 in XXXX with preterminal @entity177 .

@entity1 @entity18279 @entity10692 @entity3528 @entity177 @entity460 @entity1011 @entity3151
BACKGROUND: @entity3528 commonly evolves, as the glomerular filtration rate falls. The metabolic and skeletal effects of a possible remedy, @entity18279 , have not been studied in @entity1 with preterminal @entity177 . METHODS: @entity1 with a mean @entity1011 clearance of approximately 30 ml/min took @entity18279 for 24 weeks at doses which provided 507 or 1,521 mg @entity460 /day with meals. Metabolic determinations were made at intervals of 4-8 weeks, and the bone mineral density (BMD) was measured at the beginning and at the end of the trial. RESULTS: The low-dose regimen produced no metabolic or skeletal effect. In subjects prescribed the high-dose regimen, the 24-hour urine @entity3151 excretion fell from 0.53 mg/mg @entity1011 to values ranging from 0.34 to 0.41 mg/mg @entity1011 . The theoretical @entity3151 threshold concentration rose by a maximum of 38.6%, and the serum @entity3151 concentration did not change. The mean serum @entity460 concentration rose by a maximum of 7.2%. The mean fractional changes in parathyroid hormone and @entity10692 concentrations ranged from -27.0 to -39.6% and from -5.0 to -20.3%, respectively. The BMD increased at L1, L3, and L4. CONCLUSION: @entity18279 prescribed to deliver 1,521 mg @entity460 /day with meals reduced parathyroid hormone and @entity10692 concentrations and increased lumbar BMD in @entity1 with preterminal @entity177 .
